AT A GLANCE
03/26/2024

Coronavirus Disease 2019 (COVID-19), Influenza, & Respiratory Syncytial Virus (RSV)

Updated weekly on Tuesdays, and current as of 3:00 p.m. on the date it was posted.

**Note:** As of October 17, 2023 this document will include updates for other respiratory diseases of public health concern, primarily influenza and respiratory syncytial virus (RSV).

Additionally, the “Guidelines and Technical documents” section [last updated July 26, 2023] will no longer be updated, but is archived as an appendix at the end of this document.

Moving forward, any news and guidance updates will be cycled through the New Content section below, as always with the dates of the latest additions *bolded.*

This document is a collation of resources for your reference. For official guidance on COVID-19, Influenza, and RSV in Ontario, please visit the Ministry of Health (COVID-19 | The Flu | RSV).

Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Content</td>
<td>3</td>
</tr>
<tr>
<td>Public Health Agencies</td>
<td>3</td>
</tr>
<tr>
<td>Public Health Agency of Canada</td>
<td>3</td>
</tr>
<tr>
<td>BC Centre for Disease Control</td>
<td>3</td>
</tr>
<tr>
<td>Institut national de santé publique</td>
<td>3</td>
</tr>
<tr>
<td>CDC: Centers for Disease Control and Prevention</td>
<td>3</td>
</tr>
<tr>
<td>ECDC: European Centre for Disease Prevention and Control</td>
<td>4</td>
</tr>
<tr>
<td>FDA: U.S. Food &amp; Drug Administration</td>
<td>5</td>
</tr>
<tr>
<td>UK Government</td>
<td>5</td>
</tr>
<tr>
<td>World Health Organization</td>
<td>6</td>
</tr>
<tr>
<td>Other relevant government bodies / health care organizations</td>
<td>6</td>
</tr>
<tr>
<td>Center for Infectious Disease Research Policy</td>
<td>6</td>
</tr>
<tr>
<td>National Collaborating Centre for Environmental Health</td>
<td>7</td>
</tr>
</tbody>
</table>
New Content

Public Health Agencies

Public Health Agency of Canada | canada.ca
- COVID-19 epidemiology update: testing and variants [updated 03-26-2024]
- Key COVID updates [updated 03-26-2024]
  - Weekly change in cases: 2,296
  - Total cases: 4,944,196
  - Weekly change in deaths: 35
  - Total deaths: 58,972
  - Weekly tests reported: 32,252
  - Weekly percent positivity: 6.1%
- COVID-19 activity levels [updated 03-26-2024]
- FluWatch summary: March 10 to March 16, 2024 (week 11) [03-22-2024]
- COVID-19 daily epidemiology update [updated regularly]
- Respiratory virus detections in Canada [updated regularly]

BC Centre for Disease Control | bccdc.ca
- Epi week 11: Mar 10 to Mar 16, 2024 [03-21-2024]
- COVID-19 situation report [updated 03-21-2024]
- Genomic surveillance [updated 03-21-2024]
- Wastewater surveillance [updated 03-21-2024]
- Acute care and long-term care outbreaks [updated 03-21-2024]
- Emergency department visits for respiratory illness in BC [updated 03-21-2024]
- Viral pathogen characterization [updated 03-21-2024]
- Primary care visits for respiratory illness [updated 03-21-2024]
- Respiratory season reports [updated regularly]

Institut national de santé publique | inspq.qc.ca | inspq.qc.ca/en/
- Vaccination contre la COVID-19 : recommandations pour le printemps 2024 [03-20-2024]
- Surveillance de l'influenza et des infections respiratoires virales [03-04-2024]

CDC: Centers for Disease Control and Prevention | cdc.gov
- Ventilation can reduce exposure to respiratory viruses in indoor spaces [03-22-2024]
- Weekly U.S. influenza surveillance report [03-22-2024]
  - Seasonal influenza activity remains elevated but is decreasing nationally. Activity is decreasing or stable in nine of the 10 HHS regions; however, the Pacific Northwest reported a slight increase this week.
  - Nationally, percent positivity for both influenza A and B decreased compared to last week.
  - Nationally, outpatient respiratory illness declined but remains above baseline.\(^1\) Region 2 is below their baseline, while all other HHS regions remain at or above their region-specific baselines.
Nationally, the number of weekly flu hospital admissions has been decreasing since January.

During Week 11, of the 426 viruses reported by public health laboratories, 275 (64.6%) were influenza A and 151 (35.4%) were influenza B. Of the 198 influenza A viruses subtyped during Week 11, 87 (43.9%) were influenza A(H1N1)pdm09 and 111 (56.1%) were A(H3N2).

Five influenza-associated pediatric deaths occurring during the 2023-2024 season were reported to CDC during Week 11, bringing the season total to 121 pediatric deaths.

CDC estimates that there have been at least 30 million illnesses, 340,000 hospitalizations, and 21,000 deaths from flu so far this season.

CDC recommends that everyone 6 months and older get an annual flu vaccine as long as influenza viruses are spreading. Vaccination can still provide benefit this season.

There also are prescription flu antiviral drugs that can treat flu illness; those should be started as early as possible and are especially important for higher risk patients.

Flu viruses are among several viruses contributing to respiratory disease activity. CDC is providing updated, integrated information about COVID-19, flu, and RSV activity on a weekly basis.

- Respiratory Virus Data Channel weekly snapshot [updated 03-22-2024]
- Severe viral respiratory illness [updated 03-22-2024]
- Respiratory virus activity levels [updated 03-22-2024]
- Groups most impacted—emergency department visits [updated 03-22-2024]
- Vaccination trends—children [updated 03-22-2024]
- Symptoms of COVID-19 [updated 03-15-2024]
- COVID-19 treatments and medications [updated 03-15-2024]
- Immunization and Respiratory Diseases Bulletin [updated regularly]
- COVID Data Tracker [updated regularly]
- Respiratory virus index [updated regularly]

ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu

- Communicable disease threats report, 17-23 March 2024, week 12 [03-22-2024]
- The untold story: new report reveals 7000 additional TB deaths during COVID-19 pandemic [03-21-2024]
- Public health and social measures for health emergencies and pandemics in the EU/EEA: recommendations for strengthening preparedness planning [03-20-2024]
- ECDC issues recommendations for strengthening emergency and pandemic preparedness planning [03-20-2024]
- After-action review of the public health response of Slovenia to the COVID-19 pandemic [03-20-2024]
- Overview of respiratory virus epidemiology in the EU/EEA weekly overview (week 11, 2024) [03-19-2024]

ECDC and the WHO Regional Office for Europe have jointly developed the European Respiratory Virus Surveillance Summary (ERVISS)

- Syndromic surveillance in primary and secondary care indicate that respiratory activity is decreasing but remains above baseline levels in under half of reporting EU/EEA countries. The activity is largely driven by influenza.
All indicators pointed to elevated but decreasing influenza activity in the EU/EEA.

At the EU/EEA level, a decreasing trend in pooled sentinel primary care positivity for influenza has been observed since week 4, 2024, although the majority of reporting countries remained above the 10% positivity threshold for influenza.

The majority of countries now report medium or low levels of influenza intensity, widespread but decreasing geographical spread, and baseline rates of influenza-like illness (ILI). Stable or decreasing trends in indicators of activity and severe disease were also observed in most reporting countries.

A(H1)pdm09 continues to be the most commonly detected virus in the EU/EEA. Influenza B is now dominant in five countries although the number of influenza B detections remain low overall.

Interim influenza vaccine effectiveness estimates for the 2023–2024 season indicate that up to 53% and 44% of vaccinated individuals in primary care or hospital settings, respectively, were protected against mild and severe influenza.

- RSV activity continued to decrease to low levels at the EU/EEA level and in most reporting countries.
- SARS-CoV-2 activity remained low in all EU/EEA countries.

**FDA: U.S. Food & Drug Administration | fda.gov**

- FDA roundup: March 22, 2024 [03-22-2024]
- Fact sheet for healthcare providers: Emergency Use Authorization of Pemgarda (pemivibart) [03-22-2024]
  - “The U.S. FDA has issued an EUA for the emergency use of the unapproved product PEMGARDA (pemivibart), a SARS-CoV-2 spike protein-directed attachment inhibitor, for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg)”
- Frequently asked questions on the emergency use authorization of Pemgarda [03-22-2024]
- Fact sheet for patients, parents, and caregivers Emergency Use Authorization (EUA) of Pemgarda (pemivibart) for coronavirus disease 2019 (COVID-19) [03-22-2024]
- Vaccines and Related Biological Products Advisory Committee May 16, 2024 meeting announcement [02-26-2024]
- Coronavirus (COVID-19) update: daily roundup [updated regularly]

**UK Government | gov.uk**

- UK Health Security Agency
  - Latest childhood vaccination uptake statistics published [03-26-2024]
  - COVID-19: outbreaks in higher-risk communal accommodation settings [updated 03-25-2024]
  - COVID-19: testing for hospices [updated 03-25-2024]
  - Acute respiratory illness, including flu and COVID-19 in prisons [updated 03-25-2024]
  - Infection prevention and control in adult social care: acute respiratory infection [updated 03-25-2024]
  - COVID-19: testing from 1 April 2024 [03-25-2024]
  - Regulatory approval of Pfizer/BioNTech bivalent Original/Omicron booster vaccines [updated 03-21-2024]
• Seasonal influenza and COVID-19 vaccine uptake in frontline healthcare workers: monthly data 2023 to 2024 [updated 03-21-2024]
• National flu and COVID-19 surveillance reports: 2023 to 2024 season [updated 03-21-2024]
• Influenza vaccines marketed in the UK [updated 03-21-2024]
• Latest measles statistics published [updated 03-21-2024]
• Measles epidemiology 2023 and 2024 [updated 03-21-2024]
• COVID-19: evaluation of pilot projects to support self-isolation [03-21-2024]
• COVID-19 self-test LFD exceptional use application to MHRA [03-21-2024]
• Self-isolation compliance in cases and confirmed contacts [03-21-2024]
• COVID-19 testing and vaccination in a deprived local authority: Blackpool [03-21-2024]
• Estimating the proportion of COVID-19 cases detected by testing [03-21-2024]
• Mass asymptomatic COVID-19 testing in schools, colleges and HE institutions [03-21-2024]
• Improving testing and self-isolation take-up in low-income groups [03-21-2024]
• UK Health Security Agency Joint Modelling Team papers [03-21-2024]
• National measles guidelines [updated 03-20-2024]

World Health Organization | who.int
• PAHO/WHO: Epidemiological update outbreaks of avian influenza caused by influenza A(H5N1) in the region of the Americas - 20 March 2024 [03-22-2024]
• Terms of reference for the Technical Advisory Group on COVID-19 Vaccine Composition [03-19-2024]
• Highlights from the meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization, 11-13 March 2024 [03-19-2024]
• Respiratory virus surveillance in the WHO African Region Epidemiological Week 08, February 19 to 25, 2024 [03-18-2024]
• Laboratory biosafety guidance related to SARS-CoV-2 (COVID-19): Interim guidance, 11 March 2024 [03-11-2024]
• WHO COVID-19 dashboard [updated regularly]

Other relevant government bodies / health care organizations
• Canadian Centre for Occupational Health and Safety
  o COVID-19 health and safety resources [updated regularly]
• Statistics Canada
  o Nursing and residential care facilities, 2022 [03-19-2024]
  o Canadian health and COVID-19 survey [03-15-2024]

Center for Infectious Disease Research Policy | cidrap.umn.edu
• Survey identifies unmet child medical needs in first 2 US COVID pandemic waves [03-26-2024]
• Race, geography defined telemedicine use early in pandemic, data reveal [03-25-2024]
• More measles cases detected in Illinois, New York as US total climbs to 64 [03-25-2024]
• Study finds bivalent COVID vaccine not tied to stroke risk [03-22-2024]
New data show Paxlovid outperforms molnupiravir against severe COVID-19 outcomes [03-22-2024]

New neurologic issues less likely after severe COVID than flu, research suggests [03-22-2024]

Study highlights potential to reduce antibiotic use in newborns [03-22-2024]

Scientists caution about CDC guidance on over-the-counter drugs for COVID-19 [03-22-2024]

Probe links COVID spread to school bus riders from sick driver [03-22-2024]

Scientists link being 'double jointed' to long COVID [03-21-2024]

Simple AI tool can predict COVID vaccine uptake, researchers report [03-21-2024]

US study: Fungal infections underdiagnosed during pandemic [03-20-2024]

COVID-induced lung infection linked to heart damage [03-20-2024]

Climate change unleashing torrent of infectious disease threats, physicians caution [03-20-2024]

Providing lower oxygen levels may be more helpful in COVID ICU patients [03-19-2024]

National Collaborating Centre for Environmental Health | ncceh.ca

January 2024 environmental health research scan [01-01-2024]

December 2024 environmental health research scan [12-01-2023]

COVID-END | www.mcmasterforum.org/networks/covid-end

Global spotlight 27.1: key additions for March 2023 [03-30-2023]

ProMED | promedmail.org

Latest on COVID-19 [individual posts]

Measles - USA (27): (IL) Chicago, more cases [03-25-2024]

Avian influenza, human - Viet Nam (03): (KH) H5N1, additional information [03-24-2024]

Avian influenza, human - Viet Nam (02): (KH) H5N1, fatal [03-24-2024]

Measles - USA (26): (IL) more cases in and around Chicago [03-24-2024]

COVID-19 update (16): selected locations, vaccine effectiveness, WHO update [03-24-2024]

Avian influenza, human - Viet Nam: (KH) H5N1 [03-24-2024]

Measles - USA (25): (MI, NY, IL, FL) [03-23-2024]

Measles - Mexico: (DF) international travel [03-23-2024]

Measles - USA (24): (IL) 2 more cases in Chicago [03-22-2024]

Measles - Canada (07): more cases, potential vaccine shortage [03-22-2024]

Measles - Togo: (KA, SA) epidemic, alert [03-21-2024]

Influenza (03): India (TN) H1N1 [03-20-2024]

Measles - USA (23): CDC, advisory for vaccine use for international travel [03-20-2024]

Avian influenza, human - China (05): (GX, JX, GD) H9N2, children [03-19-2024]

Measles - USA (22): (IL) 3 more reported cases in Chicago [03-19-2024]

Data & Real-time Tracking

COVID-19 resources (case counts) | arcgis.com

Canada COVID-19 Note: has ceased updates as of 07-03-2023
COVID-19 Canada Open Data Working Group | COVID-19 CODWG

- COVID-19 in Canada (case count dashboard)

Johns Hopkins CCSE | systems.jhu.edu

- 2019-nCoV Global Cases (by Johns Hopkins CSSE)

NextStrain | nextstrain.org

- Phylogeny of SARS-like betacoronaviruses including novel coronavirus (nCoV)
- Genomic epidemiology of novel coronavirus (nCoV)
- Genomic analysis of nCoV spread. Situation report 2020-01-30

WHO | who.int

- WHO coronavirus (COVID-19) dashboard

Appendices

Guidelines and Technical documents [ARCHIVED]
The guidelines were last updated 07-26-2023; news and updated guidance can be found in the New Content section above.

Appendix I: General Guidelines [ARCHIVED]

Ontario / Canada Main Page

- Ontario guidance
- Canadian guidance (federal)

Reopening/Rebuilding Guidelines

Ontario

- ON Protection from COVID-19 and other respiratory illnesses [updated 06-15-2023]

Canada (federal) and provinces and territories (other than Ontario)

- CA Guidance for a strategic approach to lifting restrictive public health measures [06-10-2022]
- CA COVID-19: readiness criteria and indicators for easing restrictive public health measures [05-14-2021]
- BC B.C.'s response to COVID-19 [updated 02-11-2023]
- AB COVID-19 public health actions [no date]
- SK Living with COVID [no date]
- MB COVID-19 Novel Coronavirus [no date]
- QC Coronavirus disease (COVID-19) in Québec [updated 07-20-2023]
- NB [Living with COVID-19]
- NL [NL life with COVID-19]
- PEI [COVID-19]
- NS [Government’s response to COVID-19]
- NW [COVID-19]
- YT [Forging ahead: the Yukon's continuing response to COVID-19]
- NT [Nunavut’s Path: living with COVID-19]
- NCCIH: [Guidance on re-opening northern, remote, isolated, and Indigenous communities]

WHO
- [End-to-end integration of SARS-CoV-2 and influenza sentinel surveillance: compendium of country approaches]
- [Considerations for implementing and adjusting public health and social measures in the context of COVID-19: interim guidance]

ECDC
- [Conducting after-action reviews of the public health response to COVID-19: update]

Vaccinations – General

Ontario Ministry of Health
- [COVID-19 vaccine-relevant information and planning resources]

Canada (Federal)
- [Planning guidance for immunization clinics for COVID-19 vaccines]
- [For immunization providers: Interim national vaccine storage, handling and transportation guidelines for ultra-low temperature and frozen temperature COVID-19 vaccines]
- [Guidance on the use of COVID-19 vaccines in the fall of 2023]
- [Interim guidance on the use of bivalent Omicron-containing COVID-19 vaccines for primary series]
- [Summary of updates in the Canadian Immunization Guide as of June 27, 2023]

Provinces and territories (other than Ontario)
- BC [COVID-19 vaccine eligibility]

CDC
- [Stay up to date with COVID-19 vaccines including boosters]
- [COVID-19 vaccines for specific groups of people]

UK
- [COVID-19 vaccination programme]
- [COVID-19 vaccination: vaccine product information]
- [COVID-19: the green book, chapter 14a]
ECDC
- Interim public health considerations for COVID-19 vaccination roll-out during 2023 [04-05-2023]
- Interim analysis of COVID-19 vaccine effectiveness against severe acute respiratory infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 30 years and older, ECDC multi-country study – third update [modified 03-16-2023]
- Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA, [updated 03-03-2023]

Australia
- COVID-19 booster vaccine advice [updated 04-05-2023]
- Clinical recommendations for COVID-19 vaccines [updated 03-21-2023]
- ATAGI clinical guidance for COVID-19 vaccine providers [updated 02-17-2023]

Vaccinations - Adverse Effects
Canada (Federal)
- Reporting ocular adverse events following COVID-19 vaccination: Communiqué to healthcare professionals (May 30, 2022) [05-30-2022]

Provinces and territories (other than Ontario)

CDC
- Reported adverse events [updated 07-13-2023]

WHO
- Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19) [03-31-2023]

UK
- Coronavirus (COVID-19) vaccines adverse reactions [updated 03-08-2023]
- Myocarditis and pericarditis after COVID-19 vaccination [updated 01-09-2023]

Australia
- ATAGI clinical guidance on COVID-19 vaccine administration errors [updated 06-05-2023]

Background Information/Case Definitions
Ontario Ministry of Health
- Ontario case definition - coronavirus disease (COVID-19) [updated 05-00-2023]

PHAC
- National case definition: coronavirus disease (COVID-19) [updated 06-06-2023]

CDC
- Coronavirus disease 2019 (COVID-19) 2023 case definition [reviewed 02-28-2023]
WHO
- WHO COVID-19 Case definition [updated 07-22-2022]
- A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 [10-06-2021]

ECDC
- Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA [04-08-2021]

UK
- COVID-19: epidemiology, virology and clinical features [05-17-2022]

Australia
- COVID-19 disease, symptoms and variants [updated 12-09-2022]

Other
- BMJ best practice COVID-19 [updated regularly]

Laboratories

Ontario Ministry of Health
- Management of cases and contacts of COVID-19 in Ontario (version 15.2) [06-09-2023]

PHAC
- Requirements for serological antibody tests submitted under the COVID-19 interim order: guidance [modified 02-22-2023]

CDC

Miscellaneous Guidelines

PHAC
- COVID-19 and people with disabilities in Canada [updated 01-30-2023]
- Individual public health measures [updated 01-27-2023]
- Summary of evidence supporting COVID-19 public health measures [updated 01-27-2023]

CDC
- CDC Archive: Archived web material for CDC.gov is preserved on the CDC Archive Site. Note that the content on this site is for historical purposes only and is no longer being updated. The information here may be outdated and links may no longer function.

WHO
- Considerations in adjusting public health and social measures in the context of COVID-19: interim guidance [updated 03-30-2023]

Data & Surveillance

Canada
• **COVID-19 data trends** [modified 03-06-2023]
• **National surveillance guidelines for coronavirus disease (COVID-19)** [03-19-2021]

**WHO**
• **Public health surveillance for COVID-19: interim guidance** [07-22-2022]

**CDC**
• **COVID-19 serology surveillance** [03-11-2021]

**ECDC**
• **Organisation of vector surveillance and control in Europe** [12-13-2021]
• **Surveillance of COVID-19 in long-term care facilities in the EU/EEA** [11-29-2021]

**Variants – Omicron**

**Canada**
• **SARS-CoV-2 variants: national definitions, classifications and public health actions** [08-18-2022]

**CDC**
• **What is genomic surveillance?** [updated 12-02-2022]

**UK**
• **Investigation of SARS-CoV-2 variants** [updated 03-10-2023]
• **SARS-CoV-2 variants of public health interest** [updated 03-10-2023]

**ECDC**
• **Methods for the detection and characterisation of SARS-CoV-2 variants – second update** [08-02-2022]

**Testing**

**Canada**
• **Interim guidance on the use of rapid antigen detection tests for the identification of SARS-CoV-2 infection** [07-07-2022]

**Ontario Ministry of Health**
• **Management of cases and contacts of COVID-19 in Ontario Version 15.2** [03-27-2023]
• **COVID-19 provincial testing guidance, Version 15.3** [01-25-2023]

**Canadian provinces and territories (other than Ontario)**
• **BC COVID-19: viral testing guidelines for British Columbia** [09-28-2022]

**WHO**
• **Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing** [03-09-2022]

**CDC**
• **Guidance for healthcare workers about COVID-19 (SARS-CoV-2) testing** [updated 12-20-2022]
• **Using antibody tests for COVID-19** [updated 12-16-2022]

**UK**
• **Investigation of SARS-CoV-2 variants: technical briefings** [updated 02-10-2023]
• **SARS-CoV-2 variants of public health interest** [updated 02-10-2023]

**ECDC**
Symptoms/Treatment

Canada

Ontario Ministry of Health
- Management of cases and and contacts of COVID-19 in Ontario version 15.2 [updated 03-27-2023]

BC
- Clinical practice guide for the use of therapeutics in mild-moderate COVID-19 [updated 01-10-2023]

WHO
- WHO living guideline: drugs to prevent COVID-19 [updated 03-24-2023]

CDC
- Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare providers [updated 02-09-2023]
- Clinical care information for COVID-19 [updated 01-30-2023]
- Clinical considerations for care of children and adults with confirmed COVID-19 [updated 01-27-2023]
- Clinical considerations for care of children and adults with confirmed COVID-19 [updated 01-27-2023]
- Care for breastfeeding people: interim guidance on breastfeeding and breast milk feeds in the context of covid-19 [02-25-2022]

US NIH
- COVID-19 treatment guidelines [updated 03-06-2023]

UK
- Find help and support if you have long COVID [updated 03-29-2023]

COVID-19 Diagnosis in Children

Canada

WHO
- A clinical case definition for post COVID-19 condition in children and adolescents by expert consensus [02-16-2023]

CDC
- Information for Pediatric Healthcare Providers [02-10-2023]
Other
• American Academy of Pediatrics What is the case definition of multisystem inflammatory syndrome in children (MIS-C) interim guidance [02-08-2023]

Post-COVID-19 Condition
Canada
• Post COVID-19 condition (long COVID) [modified 03-09-2023]
Ontario
• Ontario Health Post COVID-19 condition: guidance for primary care [12-00-2022]
WHO
• Post COVID-19 condition [12-16-2021]
CDC
• Post-COVID conditions; CDC Science [updated 03-31-2023]
UK
• Long-term effects of coronavirus (long COVID) [reviewed 03-21-2023]

Case Investigation & Contact Tracing
Canada
• Public health management of cases and contacts associated with COVID-19 [01-30-2023]
Ontario
• Management of cases and contacts of COVID-19 in Ontario (version 15.2) [03-27-2022]
CDC
• Isolation and precautions for people with COVID-19 [03-21-2023]
UK
• COVID-19 rapid guideline: managing COVID-19 NICE guideline [NG191] [03-29-2023]

Infection Prevention and Control
PHAC / Health Canada
• At home: using ventilation and filtration to reduce the risk of aerosol transmission of COVID-19 [01-27-2023]
• Coronavirus disease (COVID-19): prevention and risks [01-27-2023]
• COVID-19 mask use: advice for community settings [01-30-2023]
Ontario
• COVID-19 guidance: personal protective equipment (PPE) for health care workers and health care entities version 1.0 [06-10-2022]

Canadian provinces and territories (other than Ontario)
WHO
• Infection prevention and control in the context of coronavirus disease (COVID-19): a living guideline, 13 January 2023 [01-13-2023]
ECDC
Appendix II: Guidelines for Health Sectors [ARCHIVED]

Healthcare Providers

Ontario Ministry of Health

- Management of cases and and contacts of COVID-19 in Ontario version 15.2 [03-27-2023]
- COVID-19 guidance: acute care v.9 [01-11-2023]
- COVID-19 guidance: personal protective equipment (PPE) for health care workers and health care entities version 1.0 [06-10-2022]

UK

- COVID-19: managing healthcare staff with symptoms of a respiratory infection [03-31-2023]

ECDC

- Considerations for infection prevention and control practices in relation to respiratory viral infections in healthcare settings [02-06-2023]
- Living safely with respiratory infections, including COVID-19: when to consider wearing a face covering or a face mask [06-16-2022]

Congregate Living (including Long-Term Care, Prisons, and Shelters)

Ontario Ministry of Health

- COVID-19 guidance document for long-term care homes in Ontario [04-03-2023]
- COVID-19 guidance: long-term care homes and retirement homes for public health units Version 10 [03-31-2023]

PHAC


CDC

- Guidance on management of COVID-19 in homeless service sites and in correctional and detention facilities [11-29-2022]

UK

- Acute respiratory illness, including flu and COVID-19 in prisons [04-06-2023]
- Infection prevention and control in adult social care: COVID-19 supplement [04-06-2023]
- COVID-19: outbreaks in prisons, refuges and other higher-risk accommodation settings [04-04-2023]

Other

- CSC Testing of inmates in federal correctional institutions for COVID-19 [04-12-2023]
Appendix III: Guidelines for the Community [ARCHIVED]

Travel, Transport & Borders

Ontario Ministry of Health
- Travelling during COVID-19 [01-27-2023]

Canada
- Travel advide and advisories by destination [updated often]
- COVID-19: travel, testing and borders [04-03-2023]

CDC
- COVID-19 travel recommendations by destination [updated regularly]
- Stay up to date with your COVID-19 vaccines including Boosters [04-06-2023]

UK
- COVID-19: guidance for people whose immune system means they are at higher risk [03-14-2023]

Schools / Childcare

Ontario Ministry of Health
- Management of cases and contacts of COVID-19 in Ontario version 15.2 [03-27-2023]
- COVID-19: health and safety measures for child care [08-17-2022]

PHAC

CDC
- Operational Guidance for K-12 Schools and Early Care and Education Programs to Support Safe In-Person Learning [10-05-2022]
- Schools, child care, and colleges [10-25-2022]

UK

Mental Health/Substance Use Health

Ontario Ministry of Health

PHAC
- Helping people who use substances [10-01-2022]

Provinces & Territories (excluding Ontario)
- QC The roles of public health in population mental health and wellness promotion [10-03-2022]
• BC COVID-19: harm reduction and overdose response [01-07-2022]
• QC Housing and social inequalities in health in times of COVID-19: strategies for promoting affordable quality housing [04-05-2022]
• QC Preventing violence and suicide within the context of the COVID-19 pandemic: courses of action [04-05-2022]
• QC Preventing loneliness in young adults in the context of a pandemic [04-05-2022]
• BC Impacts of the COVID-19 pandemic on the health and wellbeing of young adults in British Columbia [07-00-2021]
• QC Public health ethics and COVID-19: selected resources [11-00-2021]

WHO
• Mental health and COVID-19: early evidence of the pandemic’s impact: scientific brief, 2 March 2022 [03-02-2022]

Community/Workplaces
Ontario Ministry of Health
• Protection from COVID-19 and other respiratory illnesses [04-12-2023]
• COVID-19 and workplace health and safety [03-09-2023]
• COVID-19 and your employment standards protections [06-26-2022]
• Outbreak guidance: workplace and living settings for seasonal international agriculture workers (IAWs) [09-08-2022]

PHAC
• Summary of evidence supporting COVID-19 public health measures [01-27-2023]
• Community based public health measures [01-27-2023]
• How businesses and employees can stay safe while operating during COVID-19 [01-27-2023]
• Accessing public health support for First Nations communities [08-05-2022]
• COVID-19 and people with disabilities in Canada [01-30-2023]
• COVID-19 mask use: advice for community settings [01-30-2023]

WHO
• The generic all-hazards risk assessment and planning tool for mass gathering events [01-12-2023]

CDC
• Specific settings [12-07-2022]

UK
• Infection prevention and control in adult social care: COVID-19 supplement [04-04-2023]
• Living safely with respiratory infections, including COVID-19 [06-16-2022]

Other
• CCOHS daycares [07-14-2022]